{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:01Z","timestamp":1707524581639},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"DOI":"10.7759\/cureus.22679","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T11:45:41Z","timestamp":1646048741000},"source":"Crossref","is-referenced-by-count":1,"title":["Varicella-Zoster Reactivation in a Non-immunized Elderly Multiple Sclerosis Patient While on Delayed-Release Dimethyl Fumarate With Grade 2 Lymphopenia and Profoundly Low CD4+ and CD8+ Cell Counts: A Case Report"],"prefix":"10.7759","author":[{"given":"Bob","family":"Daripa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Lucchese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315596994","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake EE","year":"2015","unstructured":"Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015, 1:10.1177\/2055217315596994","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01117-y","article-title":"Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies","volume":"21","author":"Smith TE","year":"2021","unstructured":"Smith TE, Kister I. Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies. Curr Neurol Neurosci Rep. 2021, 21:36. 10.1007\/s11910-021-01117-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger JR","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al.. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013, 80:1430-8. 10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113177","article-title":"Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects","volume":"10","author":"Fischer S","year":"2021","unstructured":"Fischer S, Proschmann U, Akg\u00fcn K, Ziemssen T. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells. 2021, 10:3177. 10.3390\/cells10113177","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina T","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, et al.. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014, 76:802-12. 10.1002\/ana.24286","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000203","article-title":"Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate","volume":"3","author":"Ma BB","year":"2016","unstructured":"Ma BB, Ostrow LW, Newsome SD. Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2016, 3:e203. 10.1212\/NXI.0000000000000203","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1982.00340150091017","article-title":"Immune responses to varicella-zoster in the aged","volume":"142","author":"Burke BL","year":"1982","unstructured":"Burke BL, Steele RW, Owen W. Beard,  Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982, 142:291-3. 10.1001\/archinte.1982.00340150091017","journal-title":"Arch Intern Med"},{"key":"ref8","article-title":"Tecfidera [package insert]. Cambridge. MA: Biogen","year":"2013","unstructured":"FDA Approved Labeling Text. Tecfidera\u2122 (Dimethyl Fumarate) Delayed-Release Capsules [package insert]. 2013 (ed): Biogen Idec, Inc., Cambridge, Massachusetts; 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204063lbl.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506151","article-title":"PML in patients treated with dimethyl fumarate","volume":"373","author":"Nieuwkamp DJ","year":"2015","unstructured":"Nieuwkamp DJ, Murk JL, van Oosten BW. PML in patients treated with dimethyl fumarate. N Engl J Med. 2015, 373:582-4. 10.1056\/NEJMc1506151","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000800","article-title":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS","volume":"10","author":"Chan A","year":"2020","unstructured":"Chan A, Rose J, Alvarez E, et al.. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020, 10:510-9. 10.1212\/CPJ.0000000000000800","journal-title":"Neurol Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320918619","article-title":"Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis","volume":"6","author":"Buckle G","year":"2020","unstructured":"Buckle G, Bandari D, Greenstein J, et al.. Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2020, 6:2055217320918619. 10.1177\/2055217320918619","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86885-varicella-zoster-reactivation-in-a-non-immunized-elderly-multiple-sclerosis-patient-while-on-delayed-release-dimethyl-fumarate-with-grade-2-lymphopenia-and-profoundly-low-cd4-and-cd8-cell-counts-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:28Z","timestamp":1707507568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86885-varicella-zoster-reactivation-in-a-non-immunized-elderly-multiple-sclerosis-patient-while-on-delayed-release-dimethyl-fumarate-with-grade-2-lymphopenia-and-profoundly-low-cd4-and-cd8-cell-counts-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.22679","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}